pepdex
← Back to index
050

FOXO4-DRI

FOXO4 dominant-negative interfering peptide. Selectively triggers apoptosis in senescent cells by disrupting FOXO4-p53 interaction. Animal-model senolytic with strong age-reversal data in mice.

Longevity
Evidence: Limited
Half-life
~hours
Route
Subcutaneous
Cycle
Short pulses (3-5 days)
Schedule
Pulsed dosing, not continuous
In plain English

FOXO4-DRI is a senolytic peptide — it selectively kills senescent ('zombie') cells that accumulate with age and drive inflammation. The mouse data is dramatic: improved fur, kidney function, fitness in old mice. Human data is essentially nonexistent.

Status & legality
Natty?
Not natty
FDA
Not approved

Not FDA approved. Pre-clinical research compound (animal-model senolytic data).

Compounding
Not classified

Not formally categorized in the FDA bulks lists.

WADA
Not listed
Prescribed

Not prescribed in conventional medicine.

Who it's for

  • Researchers studying senolytics
  • Longevity-research contexts under medical guidance
  • Educational reference — limited human safety data

What to expect

  1. Week 1

    Mouse-model markers (improved fur density, kidney function, fitness) emerged within 10 days.

  2. Week 4

    Off-pulse. Effects in mice persisted for weeks.

  3. Week 8

    No human long-term data exists.

How it works (mechanism)

Dominant-negative interfering peptide that disrupts the FOXO4-p53 interaction. In senescent cells, FOXO4 normally protects against p53-driven apoptosis; blocking the interaction selectively triggers death of senescent ('zombie') cells.

Dosing protocol

No standardized human dose. Mouse-model dosing pulsed at 5 mg/kg every other day for 3 doses.

Stacks well with

Standalone — senolytic effect is the whole point

Side effects

01Limited human safety data
02Theoretical: off-target apoptosis in healthy tissue
03Injection-site reaction

When NOT to use

  • Active malignancy (apoptotic effects on cells in unstable states)
  • Pregnancy / nursing
  • Anyone risk-averse to pre-clinical-only data

Bloodwork to monitor

  • CBC and basic metabolic panel if researching

Common mistakes

  • Treating it as a longevity 'drug' (it's pre-clinical)
  • Running long cycles instead of short pulses
  • Stacking with other experimental compounds

Educational only. User-specific dosing is between you and a qualified provider.

Frequently asked

What is FOXO4-DRI?+
FOXO4-DRI is a senolytic peptide — it selectively kills senescent ('zombie') cells that accumulate with age and drive inflammation. The mouse data is dramatic: improved fur, kidney function, fitness in old mice. Human data is essentially nonexistent.
Is FOXO4-DRI FDA approved?+
Not FDA approved. Pre-clinical research compound (animal-model senolytic data).
Is FOXO4-DRI banned by WADA?+
FOXO4-DRI is not currently on the WADA prohibited list.
Are you still natty after taking FOXO4-DRI?+
No. FOXO4-DRI is a performance-enhancing peptide and would disqualify a strict natty claim.
Do doctors prescribe FOXO4-DRI?+
Not prescribed in conventional medicine.
What's the typical dose of FOXO4-DRI?+
No standardized human dose. Mouse-model dosing pulsed at 5 mg/kg every other day for 3 doses.
What are the side effects of FOXO4-DRI?+
Common side effects include: Limited human safety data; Theoretical: off-target apoptosis in healthy tissue; Injection-site reaction. Less common effects and full safety details are on the entry page.
How long until FOXO4-DRI starts working?+
Mouse-model markers (improved fur density, kidney function, fitness) emerged within 10 days.